


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE AND HYGRIA THERAPEUTICS ENTER INTO
GLOBAL STRATEGIC COLLABORATION VALUED
AT OVER HKD500 MILLION
TO CO-DEVELOP NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, InSilico Medicine and Hygria Therapeutics Co., Ltd (“**Hygria Therapeutics**”), an incubate of Shenzhen Pengfu Fund of Fosun Health Capital (as defined below) and Fosun Pharma, have entered into an exclusive license and co-development agreement (the “**Agreement**”) for InSilico Medicine’s ISM8969 program (the “**Collaboration**”).

Through the Collaboration, the two parties aim to accelerate the global advancement of ISM8969 – an orally available, brain-penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.

Under the terms of the Agreement, InSilico Medicine grants Hygria Therapeutics worldwide rights to research, develop, register, manufacture, and commercialize ISM8969, with each party holding 50% of the global rights and interests to the program. In return, InSilico Medicine is eligible to receive upfront and milestone payments totaling up to USD66 million (equivalent to approximately HKD514.8 million), including an initial upfront payment of USD10 million (equivalent to approximately HKD78 million) to be received within 30 days from the Agreement’s effective date.

About ISM8969

ISM8969, a potential best-in-class NLRP3 inhibitor, was discovered and optimized using Chemistry42, Insilico Medicine's proprietary generative chemistry engine. Preclinical data has demonstrated the molecule's robust efficacy, favorable safety profile, and marked anti-inflammatory activity in various disease models. Importantly, ISM8969 achieves desirable blood-brain barrier (BBB) penetration, a critical advantage that enables it to cross the natural protective barrier between the central nervous system and the bloodstream, and holding great promise for treating neuroinflammation-related diseases.

Based on promising preclinical data, Insilico Medicine nominated ISM8969 as a preclinical candidate and has conducted extensive evaluations of the molecule across multiple neurological disease models.

About Hygtia Therapeutics

Hygtia Therapeutics, an innovative biotechnology company incubated by the Shenzhen Pengfu Biopharmaceutical Industry Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (“**Shenzhen Pengfu Fund of Fosun Health Capital**”) and Fosun Pharma, was founded in August 2025 with a focus on autoimmune diseases and related areas. The company is committed to a global product strategy, introducing and developing pipelines with “best-in-class” potential worldwide. Through efficient and effective research & development capabilities, it aims to provide patients with breakthrough treatment options.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, January 20, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.

For the purpose of this announcement, all figures in HKD are calculated based on the exchange rate of approximately USD1.00 to HKD7.80.